Every Claim We Publish, and Where It Came From

This is the fourth temporary extension. Each of the previous three was issued close to its expiry date, so the position may change late in 2026.

No final rule and no withdrawal notice has been published. A rule can also be shelved without a formal withdrawal, so this should not be read as a statement that the DEA intends to finalise it.

Federal DEA telemedicine flexibilities run separately and expire at the end of 2026, and they require video rather than a phone call. Spravato cannot be prescribed for home use in any case, because it must be given in a certified setting.

We confirmed the absence by searching the full preferred drug list effective 1 July 2026.

The state document does not name a specific number of prior antidepressants that must have failed, so we do not publish one. It also contains no REMS wording, though the federal REMS rules apply regardless.

The programme covers the medicine, not the office visit or the two-hour observation, which is often the larger share of the bill. The official terms state that a yearly maximum applies but do not publish the amount, so we do not either. Terms are set per calendar year.

Wholesale acquisition cost is published only in paywalled pricing compendia. The figures here are seven years old and come from a secondary source, so we do not use them to produce a dollar estimate — the estimator suppresses Spravato cash figures rather than presenting a number this weak.

Deductible and premium amounts are set annually and change each January.

This is a national policy, so it reads the same wherever you live — which is why it is recorded once here rather than repeated in each state. UnitedHealthcare runs parallel medical and pharmacy versions; which one applies depends on how your clinic bills, and prior approval is needed either way.

This describes one commercial insurer. It does not describe any state Medicaid programme, none of which publishes criteria for racemic ketamine either way.

Sunshine Health's document carries no revision date and its requirement predates the FDA's monotherapy approval — worth asking whether it still applies. We could not locate Humana's Florida commercial policy, so we make no claim about it.

Based on five Florida clinics that publish prices. Miami-area concierge practices generally do not publish any, and they sit above this band.

One clinic is not a band. Treat this as an example of what one Florida clinic charges, not as what you should expect.

This is a national company charging the same price everywhere, not a Florida market rate, and it is sold as a course rather than per session. Per-session figures quoted in marketing are derived from the subscription, not separately payable.

Our estimator does not produce a self-pay Spravato figure, because there is no Florida evidence strong enough to build one on.

Esketamine has no separate DEA listing; it is covered as an enantiomer of ketamine, and the Spravato label carries the CIII designation.

This applies to the treatment-resistant depression indication only. The separate indication for major depressive disorder with acute suicidal ideation still requires an oral antidepressant — see spravato.approval_mdd_si. Widely-cited secondary sources give 21 January 2025; that is the manufacturer's announcement date, not the FDA action date on the approval letter.

The label lists a different set for the major-depressive-disorder-with-acute-suicidality indication. The two lists should not be conflated.

This is a narrative review, not a systematic review, and it reports mixed clinical findings. It does not support any personal recovery timeline.

Commercial payers and state Medicaid programmes each publish their own prior-authorisation wording; the clinical definition and the coverage definition are not always identical.

Trial populations are selected, monitoring is intensive, and individual response cannot be predicted from group averages.

This is research evidence, not an FDA approval. Off-label use remains lawful medical practice when a licensed clinician judges it appropriate.

Do not read this as a treatment recommendation. A bipolar diagnosis changes the assessment and the risk profile; only a treating clinician can decide.

The Spravato label focuses on dissociation, sedation, abuse potential and suicidal thoughts rather than a dedicated mania-switch section; the clinical risk is also described in the bipolar-depression literature cited on this page.

Most cystitis case series describe chronic recreational exposure, not a standard six-infusion clinic course. Absence of a published clinic-dose incidence figure is not proof of zero risk.

Schedule status describes abuse potential relative to other controlled drugs; it is not a prediction that a monitored clinic course will produce dependence.

Employers, courts and sports bodies may order expanded panels. If a drug test is pending, disclose prescribed treatment to the medical review officer rather than relying on a generalisation.

Spravato cannot be taken at home under the REMS. Compounded at-home racemic products are a different regulatory pathway and are not REMS-certified substitutes.

Florida law requires the physician assistant prohibited-drug list to include general anaesthetics, and ketamine is labelled as one. Whether that reaches the low doses used for depression is unsettled, and no Florida board has ruled on it.

Florida separately treats fee-splitting and patient brokering as serious offences, so the absence of a corporate-practice ban does not mean referral arrangements are unregulated.

If the system is unavailable, the prescriber must record why and may not prescribe more than a three-day supply. That three-day figure is a ceiling during an outage, not a general exemption.

Spravato is the harder case: it is genuinely prescribed even though you take it at the clinic. No Florida guidance addresses medicines dispensed by a pharmacy to a clinic, so we do not state a settled answer.